CoChat

Polygenic hazard score: an enrichment marker for Alzheimer’s associated amyloid and tau deposition

Open access
For the Alzheimer’s Disease Neuroimaging Initiative, Tan, Chin Hong, Fan, Chun Chieh, Mormino, Elizabeth C., Sugrue, Leo P., Broce, Iris J., Hess, Christopher P., Dillon, William P., Bonham, Luke W., Yokoyama, Jennifer S., Karch, Celeste M., Brewer, James B., Rabinovici, Gil D., Miller, Bruce L., Schellenberg, Gerard D., Kauppi, Karolina, Feldman, Howard A., Holland, Dominic, McEvoy, Linda K., Hyman, Bradley T., Bennett, David A., Andreassen, Ole A., Dale, Anders M., Desikan, Rahul S. · 2018 · Acta Neuropathologica
Cited by 98

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

There is an urgent need for identifying nondemented individuals at the highest risk of progressing to Alzheimer’s disease (AD) dementia. Here, we evaluated whether a recently validated polygenic hazard score (PHS) can be integrated with known in vivo cerebrospinal fluid (CSF) or positron emission tomography (PET) biomarkers of amyloid, and CSF tau pathology to prospectively predict cognitive and clinical decline in 347 cognitive normal (CN; baseline age range = 59.7–90.1, 98.85% white) and 599 mild cognitively impaired (MCI; baseline age range = 54.4–91.4, 98.83% white) individuals from the Alzheimer’s Disease Neuroimaging Initiative 1, GO, and 2. We further investigated the association of PHS with post-mortem amyloid load and neurofibrillary tangles in the Religious Orders Study and Memory and Aging Project (ROSMAP) cohort (N = 485, age at death range = 71.3–108.3). In CN and MCI individuals, we found that amyloid and total tau positivity systematically varies as a function of PHS. For individuals in greater than the 50th percentile PHS, the positive predictive value for amyloid approached 100%; for individuals in less than the 25th percentile PHS, the negative predictive value for total tau approached 85%. High PHS individuals with amyloid and tau pathology showed the steepest longitudinal cognitive and clinical decline, even among APOE ε4 noncarriers. Among the CN subgroup, we similarly found that PHS was strongly associated with amyloid positivity and the combination of PHS and biomarker status significantly predicted longitudinal clinical progression. In the ROSMAP cohort, higher PHS was associated with higher post-mortem amyloid load and neurofibrillary tangles, even in APOE ε4 noncarriers. Together, our results show that even after accounting for APOE ε4 effects, PHS may be useful in MCI and preclinical AD therapeutic trials to enrich for biomarker-positive individuals at highest risk for short-term clinical progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-017-1789-4

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 98

Metadata

Authors
Initiative, F. T. A. D. N., Tan, C. H., Fan, C. C., Mormino, E. C., Sugrue, L. P., Broce, I. J., Hess, C. P., Dillon, W. P., Bonham, L. W., Yokoyama, J. S., Karch, C. M., Brewer, J. B., Rabinovici, G. D., Miller, B. L., Schellenberg, G. D., Kauppi, K., Feldman, H. A., Holland, D., McEvoy, L. K., Hyman, B. T., Bennett, D. A., Andreassen, O. A., Dale, A. M., & Desikan, R. S.
Venue
Acta Neuropathologica
Published
2017-11-24
Volume
135
Issue
1
Pages
85-93
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2951267899
Cited by
98
References
13
FWCI
7.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.